AbbVie vs Eli Lilly

AbbVie and Eli Lilly are both leading pharmaceutical companies in the healthcare industry, known for their innovative products and strong financial performance. Investors often compare the two companies' stocks due to their similar market capitalization and revenue streams. AbbVie boasts a diverse product portfolio, including the best-selling drug Humira, while Eli Lilly is known for its strong pipeline of medications and focus on research and development. Understanding the differences and similarities between these two stocks can help investors make informed decisions in their investment strategies.

AbbVie

Eli Lilly

Stock Price
Day Low	$191.22
Day High	$196.18

Year Low	$135.85
Year High	$199.95
Yearly Change	47.18%

Revenue
Revenue Per Share	$31.09
5 Year Revenue Growth	0.45%
10 Year Revenue Growth	1.60%

Profit
Gross Profit Margin	0.72%
Operating Profit Margin	0.27%
Net Profit Margin	0.10%

Stock Price
Day Low	$907.80
Day High	$926.22

Year Low	$547.61
Year High	$972.53
Yearly Change	77.60%

Revenue
Revenue Per Share	$43.20
5 Year Revenue Growth	0.81%
10 Year Revenue Growth	0.77%

Profit
Gross Profit Margin	0.81%
Operating Profit Margin	0.27%
Net Profit Margin	0.19%

AbbVie

Eli Lilly

Financial Ratios
P/E ratio	63.57
PEG ratio	4.83
P/B ratio	50.07
ROE	57.35%

Payout ratio	201.82%
Current ratio	0.81
Quick ratio	0.71
Cash ratio	0.31

Dividend
Dividend Yield	3.23%
5 Year Dividend Yield	10.52%
10 Year Dividend Yield	13.98%
AbbVie Dividend History

Financial Ratios
P/E ratio	112.07
PEG ratio	-32.87
P/B ratio	60.67
ROE	60.72%

Payout ratio	59.60%
Current ratio	1.11
Quick ratio	0.87
Cash ratio	0.12

Dividend
Dividend Yield	0.55%
5 Year Dividend Yield	14.97%
10 Year Dividend Yield	8.71%
Eli Lilly Dividend History

AbbVie or Eli Lilly?

When comparing AbbVie and Eli Lilly, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between AbbVie and Eli Lilly.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. AbbVie has a dividend yield of 3.23%, while Eli Lilly has a dividend yield of 0.55%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. AbbVie reports a 5-year dividend growth of 10.52% year and a payout ratio of 201.82%. On the other hand, Eli Lilly reports a 5-year dividend growth of 14.97% year and a payout ratio of 59.60%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with AbbVie P/E ratio at 63.57 and Eli Lilly's P/E ratio at 112.07. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. AbbVie P/B ratio is 50.07 while Eli Lilly's P/B ratio is 60.67.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, AbbVie has seen a 5-year revenue growth of 0.45%, while Eli Lilly's is 0.81%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with AbbVie's ROE at 57.35% and Eli Lilly's ROE at 60.72%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $191.22 for AbbVie and $907.80 for Eli Lilly. Over the past year, AbbVie's prices ranged from $135.85 to $199.95, with a yearly change of 47.18%. Eli Lilly's prices fluctuated between $547.61 and $972.53, with a yearly change of 77.60%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.